System Raises $20 Million to Enhance Peptide Platform
System, a company that connects patients with licensed U.S. clinicians and pharmacy-compounded treatments, has successfully raised $20 million in a recent funding round. The round was led by Patron Fund, with participation from Vine, Courtside, Daybreak, SV Angel, and Will Ventures. This new influx of capital aims to bolster System’s vertically integrated peptide platform.
Expanding the Peptide Platform
System plans to use the newly raised funds to expand its platform, which currently facilitates the connection of patients to clinicians who evaluate health histories and determine personalized treatment protocols. These treatments are compounded by certified U.S. pharmacies and shipped directly to patients. The company is looking to broaden access to its services and continue building its infrastructure across the peptide supply chain.
The company is also working towards greater control over its supply chain. It has already integrated a compounding pharmacy within its network and is planning to add a raw-ingredient manufacturing capability. This effort is part of System's strategy to position itself between high-cost concierge clinics and less structured sources of peptide access.
Market Context
The global peptide therapeutics market is projected to reach $163 billion by 2026. System is positioning itself to capture a share of this expanding market. The company also anticipates changes in the regulatory environment, as the FDA recently approved six additional peptides that licensed compounding pharmacies can legally prepare.
Leadership Insight
Adam Steinle, Founder and CEO of System, is at the helm of these strategic developments. The company emphasizes transparency and quality control, with its products being independently lab tested and clinicians thoroughly reviewed.
Strategic Use of Funds
The funds will primarily be used to enhance System’s platform and improve its supply chain operations. This includes broadening access to its services, adding manufacturing capabilities, and ensuring quality control measures are maintained.
System’s treatments, such as Glutathione, GHK-CU, MIC+B12, NAD+, and Sermorelin, are available across all 50 states, subject to individual state telehealth regulations.